{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T16:12:06Z","timestamp":1751904726099},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vaccine-induced immune thrombotic thrombocytopenia (VITT) has been reported in association with the coronavirus disease 2019 preventative adenovirus vector-based vaccines ChAdOx1 nCoV-19 (Oxford\/AstraZeneca) and Ad26.COV2.S (Janssen\/Johnson &amp; Johnson) in hundreds of recipients across the globe. VITT is characterized by thrombosis, typically at unusual sites, low fibrinogen, and elevated plasma D-dimer, generally manifesting between 4 and 28 days following vaccination. Detection of anti-platelet factor antibodies using an enzyme-linked immunosorbent assay (ELISA) is often confirmatory. Although several similar principles subside in most diagnostic criteria for VITT, the presentation of a positive ELISA assay, use of expert hematology and neurology opinion, and exclusion of possible VITT cases outside the \u201cstandard\u201d 4 to 28-day timeframe have contributed a lack of global standardization for defining VITT. Accordingly, the global and regional incidence of VITT differs according to the diagnostic pathway and case definition used. This has influenced the public perception of VITT's severity and the decision to use adenovirus vector-based vaccines for limiting severe acute respiratory syndrome coronavirus 2 infection. We hereby delineate the recognized pathogenic mechanisms, global incidence, discrepancies in diagnostic criteria, recommended treatments, and global implications to vaccine hesitancy from this coagulopathy.<\/jats:p>","DOI":"10.1055\/s-0042-1759684","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:48:46Z","timestamp":1672962526000},"page":"009-014","source":"Crossref","is-referenced-by-count":14,"title":["COVID-19 Vaccine-Associated Immune Thrombosis and Thrombocytopenia (VITT): Diagnostic Discrepancies and Global Implications"],"prefix":"10.1055","volume":"49","author":[{"given":"Ali","family":"Zidan","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelrahman","family":"Noureldin","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreya Anil","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelrahman","family":"Elsebaie","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Othman","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Molecular Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada"},{"name":"Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansura, Egypt"},{"name":"Department of Nursing, School of Baccalaureate Nursing, St. Lawrence College, Kingston, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"issue":"17","key":"ref1","doi-asserted-by":"publisher","DOI":"10.47326\/ocsat.2021.02.17.2.0","article-title":"Vaccine-induced immune thrombotic thrombocytopenia (VITT) following adenovirus vector COVID-19 vaccination","volume":"2","author":"M Pai","year":"2021","journal-title":"Science Briefs of the Ontario COVID-19 Science Advisory Table"},{"issue":"22","key":"ref2","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"A Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1515\/cclm-2021-1039","article-title":"Review and evolution of guidelines for diagnosis of COVID-19 vaccine induced thrombotic thrombocytopenia (VITT)","volume":"60","author":"E J Favaloro","year":"2021","journal-title":"Clin Chem Lab Med"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.3390\/ijms23063338","article-title":"Coagulopathy and fibrinolytic pathophysiology in COVID-19 and SARS-CoV-2 vaccination","volume":"23","author":"S Yamada","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"S 01","key":"ref5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/ijlh.13500","article-title":"COVID-19: thrombosis, thromboinflammation, and anticoagulation considerations","volume":"43","author":"J H Levy","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"02","key":"ref6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/jcm10020191","article-title":"Proposal of the definition for COVID-19-associated coagulopathy","volume":"10","author":"T Iba","year":"2021","journal-title":"J Clin Med"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1016\/S2352-3026(21)00105-8","article-title":"COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year","volume":"8","author":"J Leentjens","year":"2021","journal-title":"Lancet Haematol"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S2213-2600(21)00221-6","article-title":"Vascular mechanisms and manifestations of COVID-19","volume":"9","author":"M Levi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19","volume":"395","author":"Z Varga","year":"2020","journal-title":"Lancet"},{"issue":"09","key":"ref10","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3201\/eid2609.202095","article-title":"Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States","volume":"26","author":"R B Martines","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"02","key":"ref11","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19","volume":"383","author":"M Ackermann","year":"2020","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"151645","DOI":"10.1016\/j.anndiagpath.2020.151645","article-title":"Severe COVID-19: a multifaceted viral vasculopathy syndrome","volume":"50","author":"C M Magro","year":"2021","journal-title":"Ann Diagn Pathol"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/infdis\/jiab039","article-title":"Evidence of severe acute respiratory syndrome coronavirus 2 replication and tropism in the lungs, airways, and vascular endothelium of patients with fatal coronavirus disease 2019: an autopsy case series","volume":"223","author":"J Bhatnagar","year":"2021","journal-title":"J Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18433\/jpps31455","article-title":"Epithelial and endothelial expressions of ACE2: SARS-CoV-2 entry routes","volume":"24","author":"C Guney","year":"2021","journal-title":"J Pharm Pharm Sci"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1515\/cclm-2020-1761","article-title":"Cytokine \u201cstorm\u201d, cytokine \u201cbreeze\u201d, or both in COVID-19?","volume":"59","author":"G Lippi","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"08","key":"ref16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/CIRCULATIONAHA.120.052824","article-title":"Lack of evidence of angiotensin-converting enzyme 2 expression and replicative infection by SARS-CoV-2 in human endothelial cells","volume":"143","author":"I R McCracken","year":"2021","journal-title":"Circulation"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S2213-2600(21)00218-6","article-title":"The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity","volume":"9","author":"M F Osuchowski","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"23","key":"ref18","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia","volume":"384","author":"D B Cines","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1111\/jth.15485","article-title":"To clot or not to clot? Ad is the question-Insights on mechanisms related to vaccine-induced thrombotic thrombocytopenia","volume":"19","author":"M Othman","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"23","key":"ref20","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"M Scully","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"ref21","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"N H Schultz","year":"2021","journal-title":"N Engl J Med"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/ijlh.13629","article-title":"Laboratory testing for suspected COVID-19 vaccine-induced (immune) thrombotic thrombocytopenia","volume":"43","author":"E J Favaloro","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1053\/j.seminhematol.2022.02.002","article-title":"Epidemiology of VITT","volume":"59","author":"M Pai","year":"2022","journal-title":"Semin Hematol"},{"issue":"15","key":"ref24","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMc2210813","article-title":"Vaccine-induced immune thrombocytopenia and thrombosis after the Sputnik V vaccine","volume":"387","author":"R Herrera-Comoglio","year":"2022","journal-title":"N Engl J Med"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1515\/biol-2022-0035","article-title":"Relationship between blood clots and COVID-19 vaccines: a literature review","volume":"17","author":"S MH Atyabi","year":"2022","journal-title":"Open Life Sci"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/M22-0118","article-title":"The epidemiology of thrombosis with thrombocytopenia syndrome: analogies with heparin-induced thrombocytopenia","volume":"175","author":"T E Warkentin","year":"2022","journal-title":"Ann Intern Med"},{"issue":"04","key":"ref28","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M21-4502","article-title":"Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021","volume":"175","author":"I See","year":"2022","journal-title":"Ann Intern Med"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1111\/jth.15881","article-title":"Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: a multicenter study comprising 1284 patients","volume":"20","author":"E J Favaloro","year":"2022","journal-title":"J Thromb Haemost"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijid.2022.03.034","article-title":"Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a systematic review and meta-analysis","volume":"119","author":"A Y Kim","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"06","key":"ref34","first-page":"451","article-title":"Diagnostic and treatment recommendations from the FACME ad-hoc expert working group on the management of cerebral venous sinus thrombosis associated with COVID-19 vaccination","volume":"36","author":"Spanish Federation of Medical and Scientific Associations","year":"2021","journal-title":"Neurologia"},{"issue":"04","key":"ref35","first-page":"281","article-title":"Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET)","volume":"19","author":"P Gresele","year":"2021","journal-title":"Blood Transfus"},{"issue":"07","key":"ref38","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1161\/STROKEAHA.121.035564","article-title":"Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia","volume":"52","author":"K L Furie","year":"2021","journal-title":"Stroke"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/imj.15783","article-title":"Understanding vaccine-induced thrombotic thrombocytopenia (VITT)","volume":"52","author":"C Dix","year":"2022","journal-title":"Intern Med J"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3324\/haematol.2021.279484","article-title":"Treatment of drug-induced immune thrombocytopenias","volume":"107","author":"I Marini","year":"2022","journal-title":"Haematologica"},{"issue":"08","key":"ref42","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jth.15362","article-title":"Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination","volume":"19","author":"S Platton","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1159\/000524290","article-title":"Ischemic stroke and vaccine-induced immune thrombotic thrombocytopenia following COVID-19 vaccine: a case report with systematic review of the literature","volume":"51","author":"A Cascio Rizzo","year":"2022","journal-title":"Cerebrovasc Dis"},{"issue":"01","key":"ref44","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(21)00306-9","article-title":"Vaccine-induced immune thrombotic thrombocytopenia","volume":"9","author":"F A Klok","year":"2022","journal-title":"Lancet Haematol"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/jth.15572","article-title":"Vaccine-induced immune thrombotic thrombocytopenia (VITT): update on diagnosis and management considering different resources","volume":"20","author":"A Greinacher","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-022-31441-x","article-title":"Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021","volume":"13","author":"J V Lazarus","year":"2022","journal-title":"Nat Commun"},{"issue":"S 01","key":"ref51","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.jfma.2021.05.020","article-title":"Economic evaluation for mass vaccination against COVID-19","volume":"120","author":"W C Wang","year":"2021","journal-title":"J Formos Med Assoc"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1759684.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:49:53Z","timestamp":1672962593000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1759684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":40,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2023,1,5]]},"published-print":{"date-parts":[[2023,2]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1759684","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]}}}